Miracle Elixirs
Miracle Elixirs
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
Miracle Elixirs
Miracle Elixirs

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

pharmaceutical industry
Opinion: The “Money Culture” in Academic Biomedical Research
Opinion: The “Money Culture” in Academic Biomedical Research
David Rubenson | Mar 29, 2019
A drive for revenue is damaging basic science.
Esketamine, a Treatment for Depression, Receives FDA Approval
Esketamine, a Treatment for Depression, Receives FDA Approval
Carolyn Wilke | Mar 6, 2019
The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Abby Olena | Dec 3, 2018
YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.
The UK Pharmaceutical Industry Braces for Brexit
The UK Pharmaceutical Industry Braces for Brexit
Diana Kwon | Oct 12, 2018
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
How to Successfully Collaborate with Industry
How to Successfully Collaborate with Industry
Ashley P. Taylor | Mar 1, 2018
In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.
Allergan’s Buying Spree Rolls On
Allergan’s Buying Spree Rolls On
Bob Grant | Sep 21, 2016
The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.
Pfizer-Allergan Merger Scrapped
Pfizer-Allergan Merger Scrapped
Bob Grant | Apr 7, 2016
A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.
Shire to Buy Baxalta for $32 Billion
Shire to Buy Baxalta for $32 Billion
Tracy Vence | Jan 12, 2016
The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.